COSCIENS Biopharma Profit Margin

COSCIENS Biopharma (AEZS) currently reports a profit margin of -692.13% as of June 2024. That compares with -354.38% in the prior-year period — down 95.3% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore COSCIENS Biopharma's profit margin history and peer comparisons.

COSCIENS Biopharma's profit margin decreased from -354.38% to -692.13% — a 95.3% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

COSCIENS Biopharma's profit margin of -692.13% is lower than the Healthcare sector average of 15.29%. That is roughly 4625.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but COSCIENS Biopharma's current -692.13% should be judged against Healthcare norms (sector average: 15.29%) and against AEZS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -692.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following AEZS for alerts when major investors trade the stock.